Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$87.18
-0.4%
$103.83
$86.16
$139.06
$152.48B0.6513.46 million shs17.19 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$55.98
-1.5%
$66.69
$55.88
$109.50
$84.49B0.6218.10 million shs12.54 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$59.48
-0.9%
$65.60
$54.11
$89.98
$23.17B1.44.80 million shs5.53 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$451.38
-0.2%
$473.81
$427.84
$603.88
$160.21B1.512.23 million shs2.95 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.61%-7.06%-15.23%-19.42%-34.22%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
-1.17%-4.24%-10.76%-25.85%-46.29%
DexCom, Inc. stock logo
DXCM
DexCom
-3.05%+0.29%-4.40%-16.02%-25.90%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
-1.40%-3.27%-0.15%-5.67%-15.13%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$87.18
-0.4%
$103.83
$86.16
$139.06
$152.48B0.6513.46 million shs17.19 million shs
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$55.98
-1.5%
$66.69
$55.88
$109.50
$84.49B0.6218.10 million shs12.54 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$59.48
-0.9%
$65.60
$54.11
$89.98
$23.17B1.44.80 million shs5.53 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$451.38
-0.2%
$473.81
$427.84
$603.88
$160.21B1.512.23 million shs2.95 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-2.61%-7.06%-15.23%-19.42%-34.22%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
-1.17%-4.24%-10.76%-25.85%-46.29%
DexCom, Inc. stock logo
DXCM
DexCom
-3.05%+0.29%-4.40%-16.02%-25.90%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
-1.40%-3.27%-0.15%-5.67%-15.13%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.88
Moderate Buy$119.4337.00% Upside
Boston Scientific Corporation stock logo
BSX
Boston Scientific
2.92
Moderate Buy$93.9167.76% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.88
Moderate Buy$83.5040.38% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.65
Moderate Buy$581.9128.92% Upside

Current Analyst Ratings Breakdown

Latest ISRG, BSX, DXCM, and ABT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingBuy$84.00 ➝ $79.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$77.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$80.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$75.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price Target$81.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetBuy$95.00 ➝ $100.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetUnderweight$72.00 ➝ $67.00
5/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Lower Price TargetBuy$84.00 ➝ $75.00
4/29/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
DowngradeStrong-BuyHold
4/27/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Reiterated RatingBuy$131.00
4/24/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
DowngradeHold (C)Hold (C-)
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$44.33B3.43$6.96 per share12.52$30.26 per share2.88
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$20.07B4.14$3.97 per share14.09$17.57 per share3.19
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B4.92$2.74 per share21.68$7.66 per share7.77
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$10.06B15.88$9.26 per share48.76$49.69 per share9.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$6.52B$3.5724.4214.391.4613.90%17.62%10.01%7/16/2026 (Estimated)
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$2.90B$2.3923.4214.931.0417.29%19.17%10.77%7/22/2026 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.3425.4219.761.0419.31%33.33%13.19%N/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.86B$8.2554.7146.013.6128.15%15.98%14.07%N/A

Latest ISRG, BSX, DXCM, and ABT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion
4/22/2026Q1 2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.7930$0.80+$0.0070$0.90$5.19 billion$5.20 billion
4/21/2026Q1 2026
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.08$2.50+$0.42$2.28$2.62 billion$2.77 billion
4/16/2026Q1 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.14$1.15+$0.01$0.61$10.99 billion$11.16 billion
2/12/2026Q4 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.65$0.68+$0.03$0.68$1.25 billion$1.26 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.522.89%+10.39%70.59%54 Years
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A

Latest ISRG, BSX, DXCM, and ABT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/20/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.632.48%4/15/20264/15/20265/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.56
1.39
1.01
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.42
1.90
1.08
DexCom, Inc. stock logo
DXCM
DexCom
0.42
1.95
1.64
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.61
3.59

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.34%
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.74 billion1.73 billionOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
59,0001.49 billion1.48 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000385.87 million384.79 millionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
17,021354.16 million352.04 millionOptionable

Recent News About These Companies

UFP Tech (UFPT) Q2 2025 Earnings Transcript
Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?
Jim Cramer Believes Competitors Might Hurt Intuitive Surgical

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$87.18 -0.36 (-0.42%)
Closing price 05/5/2026 03:59 PM Eastern
Extended Trading
$87.30 +0.12 (+0.14%)
As of 05/5/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$55.98 -0.87 (-1.53%)
Closing price 05/5/2026 03:59 PM Eastern
Extended Trading
$56.49 +0.51 (+0.91%)
As of 05/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom stock logo

DexCom NASDAQ:DXCM

$59.48 -0.56 (-0.93%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$59.48 0.00 (0.00%)
As of 05/5/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$451.38 -0.97 (-0.21%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$451.30 -0.08 (-0.02%)
As of 05/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.